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Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication of
allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, so far, no large
cohort study determined the risk factors and the most effective therapeutic strategies for
TA-TMA. Thus, the present study aimed to clarify these clinical aspects based on a large
multicenter cohort. This retrospective cohort study was performed by the Kyoto Stem Cell
Transplantation Group (KSCTG). A total of 2425 patients were enrolled from 14 institutions.
All patients were aged $16 years, presented with hematological diseases, and received allo-
HSCT after the year 2000. TA-TMA was observed in 121 patients (5.0%) on day 35 (median)
and was clearly correlated with inferior overall survival (OS) (hazard ratio [HR], 4.93). Pre-
and post-HSCT statistically significant risk factors identified by multivariate analyses
included poorer performance status (HR, 1.69), HLA mismatch (HR, 2.17), acute graft-
versus-host disease (aGVHD; grades 3-4) (HR, 4.02), Aspergillus infection (HR, 2.29), and
veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS; HR, 4.47). The response
rate and OS significantly better with the continuation or careful reduction of calcineurin
inhibitors (CNI) than the conventional treatment strategy of switching from CNI to
corticosteroids (response rate, 64.7% vs 20.0%). In summary, we identified the risk factors
and the most appropriate therapeutic strategies for TA-TMA. The described treatment
strategy could improve the outcomes of patients with TA-TMA in the future.
Introduction
Transplant-associated thrombotic microangiopathy (TA-TMA), a fatal complication, which may
develop after allogeneic hematopoietic stem cell transplantation (allo-HSCT), is a microvascular
occlusive disorder characterized by thrombocytopenia, systemic or intrarenal aggregation of
platelets, mechanical injury to erythrocytes, and ischemic organ damage.1 Despite the recent progress in
pre- and posttransplant supportive care, TA-TMA is still recognized as a devastating complication after
allo-HSCT, exhibiting a mortality rate of up to 60% to 75%.1,2
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A variety of studies have been performed to improve the non-
favorable outcomes of TA-TMA. Among these are (1) analyses of
risk factors1,3 and (2) evaluations of therapeutic strategies.4 As for
risk analyses, a wide range of factors have been proposed, such as
acute graft-versus-host disease (aGVHD), infections, unrelated or
HLA-mismatched donor grafts, and the use of a calcineurin inhibitor
(CNI) or sirolimus.1,3 However, these analyses are often associated
with epidemiological and statistical challenges, one of which is the
use of nonstandardized diagnostic criteria for TA-TMA; diagnosis is
usually based on the criteria stipulated by either Europe (European
Bone Marrow Transplant International Working Group)5 or United
States (Blood and Marrow Transplantation Clinical Trial Network)2
but sometimes clinically judged at an earlier stage before all these
criteria are fulfilled.6,7 Therefore, most retrospective studies have
been based on cases diagnosed by nonharmonized diagnostic
criteria, then studies performed using uniform criteria for TA-
TMA remain to be performed. Another challenge is represented
by selection bias; various types of complications, such as aGVHD
and veno-occlusive disease/sinusoidal obstruction syndrome (VOD/
SOS), usually appear in the acute phase after allo-HSCT when TA-
TMA is most often observed.8 Misjudgment of causality (whether
aGVHD/VOD/SOS or other complications resulted in TA-TMA and
can be risk factors for TA-TMA, or not) introduces selection bias
in the risk analysis for TA-TMA.9
The evaluation of therapeutic strategies such as the newly introduced
treatments based on recombinant human thrombomodulin (rhTM),10
defibrotide,11 and eculizumab12 is also important. However, previous
studies focusing on newer treatments have been based on relatively
small cohorts (N, 100), and their conclusions are unclear. Moreover,
conventional treatment methods as stipulated by current guidelines,2
such as replacement of CNIs with corticosteroids, should be revisited
and accurately reevaluated.
Therefore, we performed a large multicenter retrospective cohort
study and identified incidence, risk factors, appropriate therapeutic
strategies, and outcomes of TA-TMA by obtaining all necessary
data from clinical records and evaluating these using a standardized
protocol. The use of this methodology can overcome previous
limitations and lead to new insight into TA-TMA management and
total outcome improvement.
Patients and methods
Inclusion and exclusion criteria
This retrospective cohort study performed by the Kyoto Stem
Cell Transplantation Group (KSCTG) enrolled adult patients
(age $16 years) with hematological diseases who received allo-
HSCT between 1 January 2000 and 30 September 2016. Cases
receiving double-unit cord blood transplantation (CBT) and
unrelated peripheral blood stem cell transplantation (PBSCT)
were excluded because these are not yet considered standard
therapeutic options in Japan. Patients who were followed for less
than 30 days or for whom data on donor source, mismatch in
HLA, GVHD prophylaxis, date of last follow-up, and number of
HSCT were lacking were also excluded. Patients for whom we
met difficulties in terms of retrieving the original clinical records
(mostly from a relatively large time interval between allo-HSCT
and the time of patient inclusion) were also excluded. Our protocol
complied with the Declaration of Helsinki and was approved by the
institutional review board of each participating institution or the
central review board in Kyoto University Hospital. Written informed
consent was obtained individually at each institution.
TA-TMA diagnosis and therapeutic strategies
A set of diagnostic criteria for TA-TMA was established based on
conventional criteria.2,5 In this retrospective study, we first listed the
patients who were suspected with TA-TMA by attending physicians
and then by reviewing their medical records we confirmed the
diagnosis if the patients fulfilled 2 of the following diagnostic
criteria with TA-TMA: (1) presence of erythrocyte fragmentation
and schistocytes (2 counts or more per 1 high-power field) in
a peripheral blood smear, (2) concurrently increased serum
lactate dehydrogenase levels above institutional baseline, (3) de
novo prolonged or progressive thrombocytopenia (platelet count
,50 3 109/L or a 50% or greater decrease from previous
counts) or anemia (decrease of hemoglobin concentration or
increase in red blood cell transfusion requirement), (4) concurrent
renal dysfunction (doubling of serum creatinine levels relative to
baseline or 50% decrease in creatinine clearance from baseline)
and/or neurological dysfunction without other causes, and (5)
negative direct and indirect Coombs test results or a decrease
in serum haptoglobin concentration.
Therapeutic strategies for TA-TMA, including administration of rhTM,
infusion of fresh frozen plasma (FFP), plasma exchange, modulation of
CNI, and corticosteroids (CS) were performed based on the
decisions of the attending physicians. The modulation of CNI and
CS were divided into 4 groups: (1) patients whose CNI were
maintained or reduced without replacing and exchanging their
CNI type (maintenance/reduction of CNI), (2) patients whose
CNI was switched to the different type of CNI irrespective of
modulation of CS (switch to other CNIs), (3) patients whose CNI
was replaced with CS (switch to CS), and (4) patients whose CS
were increased without replacing and exchanging their CNI type
(increase of CS). All data regarding the types and the initiation
date of the therapeutic strategies were recorded and collated.
Data collection and definition of each covariate
From the KSCTG database, we extracted data on basic pretrans-
plant characteristics and posttransplant clinical courses. Data on
TA-TMA were not included in the KSCTG database, and therefore,
we reviewed medical records and extracted the data related to the
Exclusion criteria (N = 490)
Double unit CBT
Unrelated PBSCT




Adult / Allo HSCT (N = 2,915)
Final cohort (N = 2,425)
Figure 1. Schematic workflow of patient inclusion and exclusion. The
KSCTG adult allogenic stem cell transplantation cohort consisted of 2915 patients
from 17 centers. We excluded patients who fulfilled the mentioned exclusion criteria
and finally enrolled 2425 patients in this study.
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diagnosis and therapeutic strategies for TA-TMA according to
the predefined standardized diagnostic criteria listed previously.
Patients were categorized into 2 groups with respect to age
(,50 years of age vs$50 years of age), performance status (PS;
0-1 vs 2-4), hematopoietic cell transplantation comorbidity index
(HCT-CI; 0-2 vs $3). Underlying diagnoses were divided into
8 groups: acute myelogenous leukemia/myelodysplastic syn-
drome (AML/MDS), acute lymphoblastic leukemia (ALL), non-
Hodgkin lymphoma (NHL), adult T-cell leukemia/lymphoma (ATL),
chronic myelogenous leukemia (CML), multiple myeloma (MM),
aplastic anemia (AA), and other hematological diseases (others).
Patients were divided into high-risk and standard-risk groups
according to disease risk. Standard-risk was defined as follows:
(1) acute leukemia in first complete remission phase, (2) de novo
refractory anemia and ringed sideroblasts, (3) malignant lym-
phoma/MM in complete or partial remission phase, or (4) all
nonmalignant hematological diseases. All other patients were
considered high-risk patients. As for conditioning regimens,
myeloablative conditioning (MAC) and reduced-intensity condi-
tioning (RIC) were defined based on the previously published
consensus criteria.13 The year of HSCT was categorized into 2
groups (2000-2009 vs 2010-2016) based on the median
HSCT year of the entire cohort. HLA disparity in HLA-A, HLA-
B, and HLA-DR antigens was determined at serology level for
related bone marrow transplantation (BMT), related PBSCT, and
CBT; a 6/6 match was categorized as an HLA-matched group,
and the others as an HLA-mismatched group. For unrelated
BMT, HLA disparity was identified at DNA-allelic level; an 8/8
match was categorized as an HLA-matched group, and the
others as HLA-mismatched groups. Diagnosis and classification
of aGVHD were performed on the basis of traditional criteria
by the attending physicians at each center.14,15 Diagnosis of
infectious diseases, including any bacterial, fungal (Candida spp
and Aspergillus spp), and viral (cytomegalovirus [CMV], adeno-
virus, and BK virus) infections, was also performed by the
attending physicians at the respective center. Standard infection
prevention strategies were adopted in accordance with the
guidelines of the Japanese Society for Hematopoietic Cell
Transplantation and included the use of a protective environment,
prophylactic administration of antibiotics (normally fluoroquino-
lone, fluconazole, and acyclovir), and intravenous immunoglobulin
Table 1. Patient characteristics
Variables N 5 2425
Age, y








Disease risk, standard/high 1208/1217
Prior allo-HSCT, N/Y 2019/406
Conditioning regimen, MAC/RIC 1171/1146
Donor source, Rel-BM/Rel-PB/UR-BM/CB 471/422/870/662
HLA disparity, matched/mismatched 967/1458
Sex mismatch, matched/F to M/M to F 1180/549 /538
ABO mismatch, matched/major/minor/major-minor 1060/418/518/227
GVHD prophylaxis, CyA-/FK506-based 758/1667
Year of HSCT, 2000-2009/2010-2016 1147/1278
Follow-up for survivors, median (range), d 1499 (31-5943)
CB, cord blood; CyA, cyclosporine A; F to M, female donor to male recipient; M to F,
male donor to female recipient; N, no; Rel-BM, related bone marrow; Rel-PB, related
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Figure 2. Cumulative incidence of TA-TMA and its effect on survival after allo-HSCT. (A) Cumulative incidence of TA-TMA was calculated using Gray’s method.
(B) OS is shown in the Simon-Makuch plot, with TA-TMA treated as a time-dependent variable. (C) The cumulative incidence of NRM for patients with or without TA-TMA.
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Table 2. Analysis of pretransplant risk factors for the development of TA-TMA
Variables TA-TMA incidence, %
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age, y
,50 4.1 Reference Reference
$50 5.8 1.46 (1.02-2.10) .04* 1.35 (0.92-1.99) .12
Sex
Female 4.5 Reference
Male 5.3 1.14 (0.79-1.64) .49
PS
0-1 4.3 Reference Reference
2-4 8.1 1.94 (1.27-2.96) ,.01* 1.69 (1.09-2.61) .01*
HCT-CI
0-2 5.0 Reference Reference
3- 9.0 1.81 (1.09-2.99) .02* 1.65 (0.91-2.59) .10
Disease
ALL 5.3 Reference
AML MDS 4.0 0.75 (0.45-1.26) .28
NHL 6.3 1.27 (0.70-2.32) .44
ATL 6.2 1.20 (0.53-2.72) .67
CML 4.9 0.93 (0.32-2.67) .89
MM 8.3 1.61 (0.60-4.28) .34
AA 1.7 0.31 (0.04-2.30) .25
Disease risk
Standard 4.1 Reference
High 5.9 1.43 (0.99-2.05) .05
Prior allo-HSCT
N 4.6 Reference
Y 6.9 1.52 (0.99-2.31) .05
Conditioning
MAC 5.3 Reference
RIC 5.1 0.97 (0.68-1.39) .88
Donor source
Rel-BM 2.6 Reference Reference
Rel-PB 5.0 2.00 (0.98-4.06) .06 1.55 (0.77-3.12) .21
UR-BM 4.6 1.87 (0.99-3.56) .06 1.17 (0.61-2.22) .63
CB 7.1 2.89 (1.53-5.43) ,.01* 1.18 (0.60-2.30) .61
HLA mismatch
Matched 2.8 Reference Reference
Mismatched 6.4 2.25 (1.48-3.43) ,.01* 2.17 (1.34-3.52) ,.01*
Sex mismatch
Matched 4.4 Reference
F to M 5.9 1.34 (0.86-2.07) .20
M to F 5.0 1.19 (0.75-1.89) .46
ABO mismatch
Matched 5.4 Reference
Major 5.3 0.96 (0.59-1.57) .87
Minor 6.6 1.21 (0.79-1.85) .38
Major-Minor 3.1 0.55 (0.25-1.21) .14
*Statistically significant.
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replacement for hypogammaglobulinemia.16 The diagnosis of
VOD/SOS was performed based on the traditional criteria by the
attending physicians at each center.17
Regarding response to TA-TMA treatment, the patients who had
decrease of serum lactate dehydrogenase levels or fragment red
blood cells were defined as response to therapy.
Statistical analyses
The cumulative incidence for TA-TMA was calculated using
Gray’s test; death from any cause was considered a competing
risk. Overall survival (OS) was evaluated in patients with or
without TA-TMA using the Simon-Makuch method and compared
using the Cox proportional hazard model, treating TA-TMA
development as a time-dependent covariate. The cumulative
incidence of nonrelapse mortality (NRM) was calculated using
Gray’s method, considering relapse and death as competing
risks. Correlations between each pre- or posttransplant factor
and TA-TMA development were analyzed using the Fine-Gray
proportional hazards model; post-HSCT events such as aGVHD
and VOD/SOS were treated as time-dependent covariates in
correlation with TA-TMA. We evaluated the effect of each TA-
TMA treatment on clinical response using a logistic regression
model and on OS using the Cox proportional hazards model. Values
of P , .05 were considered statistically significant. Factors
appearing as significant in the univariate analysis were subjected
to the multivariate analyses. All statistical analyses were performed
using STATA (version 16.0; Stata Corp, TX) and EZR (Saitama
Medical Center, Jichi Medical University, Saitama, Japan),




We enrolled 2425 patients who received allo-HSCT in a total of 17
centers from 2000 to 2016. The schematic workflow of inclusion
and exclusion of our study patients is shown in Figure 1, and patient
characteristics are shown in Table 1. The median age at HSCT was
50 years (range, 16-74 years), and 1387 (57.2%) of the patients
were male. PS at HSCT was poor (2-4) in 359 (14.8%) patients,
and HCT-CI score was high ($3) in 213 patients (8.8%). Overall,
1234 patients were transplanted for AML/MDS, 381 for ALL, and
350 for NHL. As for disease risk, 1217 (50.2%) patients were
classified as being at high risk. With regard to donor source,
471 patients (19.4%) received related BMT, 422 (17.4%) related
PBSCT, 870 (35.9%) unrelated BMT, and 662 (27.3%) unrelated
CBT. HLAmismatch was observed for 1458 (60.2%) patients, owing
to the higher proportion of mismatched donor in CBT (91.4%) and
unrelated BMT (68.6%). The number of HLA-mismatched patients in
each donor source is shown in supplemental Table 1. The median
follow-up period for survivors was 1499 days (range, 31-5943 days).
Other pre-HSCT characteristics are summarized in Table 1.
Incidence of TA-TMA and its impact on
post-HSCT outcome
First, 134 patients who were suspected with TA-TMA by attending
physicians were listed in this retrospective study, and among them
121 patients who met these criteria were diagnosed with TA-TMA
(supplemental Figure 1). After HSCT, TA-TMA was diagnosed on
a median of 35 days (range, 3-482 days), and the cumulative
incidence of TA-TMA 12 months after HSCT was 5.0% (Figure 2A).
Among these 121 patients, 46 and 43 patients fully met the
conventional European Group for Blood and Marrow Transplanta-
tion International Working Group (EBMT IWG)18 and Blood and
Marrow Transplantation Clinical Trial Network (BMT CTN) criteria,2
respectively (supplemental Figure 1). The 1-year OS of patients with
and without TA-TMA was 6.0% and 62.1%, respectively (Figure 2B).
The development of TA-TMA correlated with remarkably inferior
OS (hazard ratio [HR], 4.93; 95% confidence interval [CI], 4.03-
6.02; P , .01), when treating TA-TMA as a time-dependent
covariate. Moreover, the 1-year NRM was significantly higher
(72.7% vs 17.4%, P , .01) in patients with TA-TMA than in those
without TA-TMA (Figure 2C).
Pre- and post-HSCT risk factors for the development
of TA-TMA
First, we examined pretransplantation risk factors for the development
of TA-TMA (Table 2). In the univariate analysis, older age (P 5 .04),
poorer PS (P, .01), higher HCT-CI score (P5 .02), CBT (P, .01),
and HLA-mismatched donor (P, .01) significantly correlated with the
development of TA-TMA (Figure 3A-C; supplemental Figure 2),
whereas other factors such as sex, underlying disease, disease
risk, prior allo-HSCT, and conditioning regimen did not correlate
(Table 2). In the multivariate analysis using the above-mentioned
significant pretransplantation factors, poorer PS (HR, 1.69;
95% CI, 1.09-2.61; P 5 .01) and HLA-mismatched donor (HR,
2.17; 95% CI, 1.34-3.52; P , .01) remained significant (Table 2).
Next, we evaluated the influence of posttransplantation risk
factors for the development of TA-TMA. In the univariate analysis,
Table 2. (continued)
Variables TA-TMA incidence, %
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
GVHD prophylaxis
CyA-based 4.5 Reference
FK506-based 5.2 1.17 (0.79-1.74) .43
Year of HSCT
2000-2009 4.4 Reference
2010-2016 5.5 1.29 (0.90-1.85) .17
*Statistically significant.
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grade 3-4 aGVHD (P, .01), Aspergillus infection (P, .01), CMV
reactivation (P , .01), hemorrhagic cystitis (P 5 .05) and VOD/
SOS (P, .01) were significantly correlated with the development
of TA-TMA (Figure 4A-B), whereas infections with bacterial,
Candida, and CMV were not (Table 3). We further performed
multivariate analysis by using the pretransplantation factors (age,
PS, HCT-CI, donor source, and HLA mismatch) and posttrans-
plantation factors (grade 3-4 aGVHD, Aspergillus infection, CMV
reactivation, hemorrhagic cystitis, and VOD/SOS). In this multi-
variate model, grade 3-4 aGVHD (HR, 4.02; 95% CI, 2.36-6.83;
P, .01), Aspergillus infection (HR, 2.29; 95% CI, 1.15-4.54; P,
.01), and VOD/SOS (HR, 4.47; 95% CI, 2.25-8.87; P, .01) were
indicated as significant risk factors (Table 3). These analyses were
performed treating post-HSCT complications as time-dependent
covariates. In the sensitivity analyses in which aGVHD and VOD/
SOS were treated as constant covariates, we also observed that
aGVHD (HR, 3.66; 95% CI, 2.45-5.48; P , .01) and VOD/SOS
(HR, 5.23; 95% CI, 3.17-8.63; P , .01) were significant risk
factors for TA-TMA.
Because both HLA-mismatched donor and grade 3-4 aGVHD
were significant risk factors, we evaluated the statistical in-
teraction between them, finding that GVHD and HLA disparity
showed significant interaction toward TA-TMA. In the subgroup
analyses regarding HLA disparity, the impact of GVHD on TA-
TMA was higher in the HLA-matched subgroup (HR, 7.65; 95%
CI, 3.00-19.5; P , .01) than that in the HLA-mismatched


















































































Figure 3. Univariate analyses of pretransplantation risk factors for TA-TMA development. The cumulative incidence of TA-TMA was calculated and compared
between (A) patients with poor PS (2-4) and those with good PS (0-1), (B) patients with an HCT-CI high score ($3) and those with a low score of 0-2, and (C) patients who





















































Figure 4. Univariate analyses of posttransplantation
risk factors for TA-TMA development. The cumulative
incidence of TA-TMA was significantly higher in patients who
developed (A) severe GVHD (grade 3-4) and (B) VOD/SOS.
GVHD and VOD/SOS were treated as time-dependent
covariates.
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Comparisons of outcomes after treatment of TA-TMA
The therapeutic strategies for TA-TMA were mainly based on the
modulation of immunosuppressants and/or addition of other
interventions. As for immunosuppressant modulation (N 5 115),
85 patients had their CNIs maintained or reduced (the dose of
CNI changed to 68.8 6 13.5% [mean 6 standard error] in
randomly selected patients), 11 patients had their CNIs switched
to a different type of CNI, 10 patients were switched from CNIs
to CS, and 9 patients had their CS increased. Meanwhile, additional
interventions were used in 86 patients; 47 patients were treated
with monotherapy such as rhTM (6; 5.1%), FFP (36; 30.5%),
or plasma exchange (4; 3.4%), and 40 patients were treated
with combination therapies as follows: FFP1rhTM (13; 11.0%),
FFP1PE (11; 9.3%), rhTM1PE (5; 4.2%), or FFP1rhTM1PE
(11; 9.3%) (supplemental Table 2).
As for the outcomes, the median OS after onset of TA-TMA in the
patients who switched their CNIs to CS was remarkably inferior to
that of the patients who maintained or reduced their CNIs (17 days;
95% CI, 7-41 vs 50 days; 95% CI, 36-75, P, .01) or to that of the
patients who switched their CNIs to a different type (vs 74 days;
95% CI, 11-355, P , .01) (Figure 5A; Table 4). In addition, the
death attributed to TA-TMA was more frequently observed in the
patients of switch to CS when compared with the patients of
maintenance/reduction of CNIs (54.5% vs 17.6%) or the patients
of switch to other CNIs (11.1%) (supplemental Table 3).
To further investigate whether switching from CNIs to CS adversely
affected the outcomes of TA-TMA, we performed multivariate
analysis focusing on these therapeutic strategies. In the multivariate
model, replacement of CNIs with CS (switch to CS) showed
significantly inferior outcomes, both in terms of response rate
(OR, 0.12; 95% CI, 0.02-0.63; P 5 .01) and in terms of OS
(HR, 3.23; 95% CI, 1.64-6.33; P , .01) compared with CNI
maintenance/reduction (Figure 5B). These findings suggested that
CNI maintenance/reduction could be a better therapeutic strategy
for TA-TMA than switching to CS.
Conversely, the prognostic impact of additional interventions was
limited. We found that rhTM did not provide any significant
improvement: response rate (OR, 0.93; 95% CI, 0.38-2.27; P 5
.87) and OS (HR, 1.06; 95% CI, 0.67-1.66; P 5 .81) (Table 4).
We observed similar results for both FFP and PE.
Discussion
This present multicenter retrospective cohort study investigating
the risk and outcome of TA-TMA revealed 2 major findings: (1) using
Table 3. Analysis of posttransplant risk factors for the development of TA-TMA
Variables
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Grade 3-4 aGVHD
N Reference Reference
Y 4.62 (2.98-7.14) ,.01* 4.02 (2.36-6.83) ,.01*
Bacterial infection
N Reference
Y 1.1 (0.81-1.74) .37
Aspergillus infection
N Reference Reference
Y 2.41 (1.32-4.39) ,.01* 2.29 (1.15-4.54) .01*
Candida infection
N Reference
Y 1.36 (0.43-4.30) .60
CMV infection
N Reference
Y 1.57 (0.64-3.76) .32
CMV reactivation
N Reference Reference
Y 2.01 (1.31-3.09) ,.01* 1.51 (0.92-2.47) .09
Hemorrhagic cystitis
N Reference Reference
Y 1.91 (1.00-3.64) .05 1.45 (0.69-3.07) .32
VOD/SOS
N Reference Reference
Y 6.39 (3.66-11.1) ,.01* 4.47 (2.25-8.87) ,.01*
Multivariate analysis was performed including significant pre-HSCT factors (age, PS, HCT-CI, donor source, and HLA mismatch).
*Statistically significant.
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predefined and uniform TA-TMA diagnostic criteria, aGVHD,
Aspergillus infection, and VOD/SOS were correlated with a signif-
icantly higher incidence of subsequent TA-TMA along with other
risk factors such as PS and HLA mismatch; and (2) the therapeutic
strategy of maintaining or slightly reducing CNI doses resulted in
significantly superior outcomes compared with conventional
strategies such as replacing CNI with CS (switching from CNI to
CS). This study is remarkable also in the sense that one of the
largest patient cohorts (N5 2425) was analyzed for incidence, risk
factors, and outcome of TA-TMA with the same protocol, including
a set of uniform diagnostic criteria for this complication.
Initially, for the diagnosis of TA-TMA, we adopted predefined and
uniform diagnostic criteria, and the set of criteria was established as
a mixture and modification of those stipulated by EBMT IWG18 and
BMT CTN,2 because clinicians usually diagnose TA-TMA and
initiate treatment as soon as just some features of the conventional
diagnostic criteria are apparent.6,7 It is widely recognized that
initiating treatment only when either set of the conventional criteria
have been completely satisfied is too late, because organ
dysfunction is already typically irreversible at this time point.6 To
encourage physicians to try and establish the diagnosis earlier,
a Japanese team introduced the concept of “pre-TMA” (defined as
a decrease of haptoglobin and progressive thrombocytopenia
without disseminated intravascular coagulopathy and Coombs test)
and proposed to initiate treatment at this point.19 Our criteria are
skewed toward a slightly later phase than those of “pre-TMA” but
would appear at a much earlier stage than the conventional
diagnostic criteria in the time course of TA-TMA progression.2,18
Using uniform diagnostic criteria for TA-TMA, we confirmed that
PS and HLA mismatch (as pretransplant factors) and aGVHD,
Aspergillus infection, and VOD/SOS (as posttransplant factors)
were significant risk factors for TA-TMA. Basic science results
revealed that aGVHD, infection, and VOD/SOS can be triggers of
TA-TMA20,21; these complications, through donor-derived T-cell
activation and production of inflammatory cytokine bursts,22,23 can
trigger vascular endothelial injury as a “final common pathway” in
TA-TMA.1,20,24
The quality of previous clinico-epidemiological studies has been
limited by selection bias. Because these posttransplant compli-
cations usually appear during the acute phase after allo-HSCT,
a careful review of clinical records and statistical maneuvers are
necessary to precisely match the causes with the consequences
(whether aGVHD has proceeded TA-TMA [ie, TA-TMA occurred
in the cohort with aGVHD] or in turn, TA-TMA was followed by
aGVHD [ie, TA-TMA occurred in the cohort without aGVHD]);
otherwise, misjudgment at this point causes selection bias and
leads to incorrect analyses of risk factors for TA-TMA. Only 1
retrospective study analyzed risk factors for TA-TMA by treating
posttransplant factors as time dependent covariates.25 However,
most of the previous studies appear to have overlooked the
importance of this particular point,26-28 and the results (aGVHD
as a risk factor for TA-TMA) are to some extent influenced by this
bias. Our analyses were performed after deliberate review and
confirmation of clinical records, especially with regard to posttrans-
plant factors, and statistical maneuvers such as treating post-HSCT
events as time-dependent variables were adopted. Of 37 patients
who experienced TA-TMA and grade 3-4 aGVHD, our clinical
record review indicated that aGVHD was followed by TA-TMA only
in 27 patients. Risk factor analysis without taking this into account
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Figure 5. Continuation of CNI instead of discontinuation improved the outcome of TA-TMA patients. (A) The survival time after TA-TMA onset of the individual
patients are shown as bar graphs. TA-TMA patients were divided into 4 groups based on their status of immunosuppressant modulation. The survival status (alive or dead) of
each patient is shown at the bottom. The median number of days of OS and 95% CI in each group are displayed. (B) OS after TA-TMA onset was more favorable in the
patients who continued the CNI treatment (maintenance/reduction) or were switched to other CNIs than in those for whom CNIs were replaced with CS (switch to CS).
3176 MATSUI et al 14 JULY 2020 x VOLUME 4, NUMBER 13
TA-TMA,9 and analyses using time-dependent covariates overcame
this bias in our study.
In addition to risk factors, we intensively scrutinized the therapeutic
strategies implemented after the diagnosis of TA-TMA, and the
result went against the conventional guideline strategy of switching
from CNI to CS or other drugs.2 This strategy was consistent with
the observation that the continuous administration of CNI can
damage vascular endothelia and deteriorate TA-TMA.29 However,
recent in vitro experiments suggested that moderate concen-
trations of CNI did not induce severe endothelial damage,
whereas extremely high CNI concentrations resulted in these
damages in a dose-dependent manner.30 These basic research
findings potentially support the continuation of CNI as far as the
serum concentration is kept in the moderate range.
The reason why prompt termination of CNI followed by the switch to
CS led to the least favorable outcome among all the therapeutic
options for TA-TMA could not be completely elucidated in this study
because of the wide variety of patient backgrounds and the small
number of this cohort. This limitation should be addressed in future
study using a larger patient cohort in a prospective manner. An
interesting observation in this study is that TA-TMA as the final
cause of death was more commonly observed in patients who were
switched from CNI to CS when compared with the other subgroups
of patients, suggesting that replacement with CS may possibly
trigger TA-TMA aggravation and/or coexisting organ damage.
Another possibility is a selection bias, that is, patients who could
not continue their CNIs because of severe organ damage were
selectively included in the CNI to CS group. The other speculation
is that the rapid decrease in CNI could aggravate the coexisting
aGVHD, which in turn resulted in fatal organ failures and/or
infections,31 although we found no statistically significant support
for this in this study. Relevant management of aGVHD may be one
of the key strategies for securing a better prognosis of TA-TMA.
Other therapeutic maneuvers such as the infusion of rhTM or FFP
administration did not show any significant improvement in the
outcome after TA-TMA in this study. A previous case series from
Japan10 suggested that the efficacy of rhTM in TA-TMA patients
might be due to its antithrombotic, anti-inflammatory, and complement-
modulating functions, but statistical analysis of the data from our larger
cohort failed to find support for their experimental therapy. Other
drugs with some potential for TA-TMA such as defibrotide11 or
eculizumab12,26,32 were not included in our analysis because these
drugs were only recently approved and have not been widely used
in our real-world cohort.
Thus, the present study analyzed TA-TMA comprehensively using
a relatively large multicenter cohort. However, some limitations to this
study exist and must be addressed. For instance, the therapeutic
strategy for each patient had not been uniformly decided and was
in fact selected at the discretion of the attending physician.
Moreover, new agents that can directly improve TA-TMA (ritux-
imab,33 defibrotide,11 and eculizumab12,26) were not used in the
cohort. Any additional therapeutic effects of these newer drugs
should be investigated in future studies in comparison with the
current strategy of maintaining or slightly reducing CNIs. Last, post-
HSCT clinical data, such as blood pressure or renal function, are
not included in this study, which can possibly work as preemptive
TA-TMA suggestion markers. Once these limitations have been
overcome, highly targeted and complete protocols for prevention
and early intervention can be provided.
In summary, we performed a large multicenter cohort retrospective
study analyzing incidence, risk factors, therapeutic strategies, and
outcomes of TA-TMA by obtaining all the necessary data from
clinical records and evaluating these based on a standardized
protocol. Our study overcame the previously mentioned challenges
such as nonuniform diagnostic criteria and selection bias. We
identified risk factors for TA-TMA and suggested the most effective





Response rate, % OR (95% CI) P Median OS, d HR (95% CI) P
Immunosuppressant
modulation
Maintenance/reduction of CNI 85 64.7 Reference 86 50 Reference
Switch to other CNIs 11 72.7 1.42 (0.35-5.89) .62 11 74 0.71 (0.35-1.44) .34
Switch to CS 10 20.0 0.12 (0.02-0.63) .01* 11 17 3.23 (1.64-6.33) ,.01*
Increase of CS 9 44.4 0.37 (0.09-1.59) .18 10 36 1.71 (0.86-3.42) .13
rhTM
N 83 59.0 Reference 85 41 Reference
Y 35 60.0 0.93 (0.38-2.27) .87 36 48.5 1.06 (0.67-1.66) .81
FFP
N 47 57.4 Reference 47 41 Reference
Y 71 60.6 1.30 (0.56-3.05) .54 74 41 1.56 (0.99-2.37) .05
PE
N 86 58.1 Reference 88 42 Reference
Y 31 64.5 1.25 (0.49-3.23) .64 32 40 1.41 (0.88-2.28) .16
*Statistically significant.
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therapeutic strategies such as continuation rather than discontin-
uation of CNI. We expect that our results and discussions could
provide clinically useful information to reduce and properly manage
TA-TMA, and in the future, to improve the overall outcome after allo-
HSCT along with the effective administration of newer drugs for
TA-TMA.
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